Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity
出版年份 2013 全文链接
标题
Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity
作者
关键词
-
出版物
mAbs
Volume 6, Issue 2, Pages 409-421
出版商
Informa UK Limited
发表日期
2013-12-12
DOI
10.4161/mabs.27457
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Neutrophils mediate antibody-induced antitumor effects in mice
- (2013) M. Albanesi et al. BLOOD
- Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
- (2013) J. Golay et al. BLOOD
- Impact of Immune Complex Size and Glycosylation on IgG Binding to Human Fc Rs
- (2013) A. Lux et al. JOURNAL OF IMMUNOLOGY
- Neutrophils as effector cells for antibody-based immunotherapy of cancer
- (2013) Marjolein van Egmond et al. SEMINARS IN CANCER BIOLOGY
- CD20 antibodies: type II to tango?
- (2012) M. H. J. van Oers BLOOD
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- Endocytosis of soluble immune complexes leads to their clearance by Fc RIIIB but induces neutrophil extracellular traps via Fc RIIA in vivo
- (2012) K. Chen et al. BLOOD
- Properties of mouse and human IgG receptors and their contribution to disease models
- (2012) P. Bruhns BLOOD
- The future of antibodies as cancer drugs
- (2012) Janice M. Reichert et al. DRUG DISCOVERY TODAY
- Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
- (2012) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Marketing approval of mogamulizumab
- (2012) Alain Beck et al. mAbs
- Molecular engineering to improve antibodies’ anti-lymphoma activity
- (2011) Matthias Peipp et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo
- (2011) Markus Biburger et al. IMMUNITY
- Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors
- (2011) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC
- (2011) Roland Repp et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
- (2011) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose
- (2011) C. Ferrara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
- (2010) S. de Haij et al. CANCER RESEARCH
- Fcγ Receptor Polymorphisms as Biomarkers for Epidermal Growth Factor Receptor Antibodies
- (2010) Thomas Valerius JOURNAL OF CLINICAL ONCOLOGY
- Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models
- (2010) William M. Siders et al. LEUKEMIA & LYMPHOMA
- Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils
- (2009) Mami Shibata-Koyama et al. EXPERIMENTAL HEMATOLOGY
- Copy number variation at theFCGRlocus includesFCGR3A, FCGR2CandFCGR3Bbut notFCGR2AandFCGR2B
- (2009) Willemijn B. Breunis et al. HUMAN MUTATION
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
- (2009) Tanja Schneider-Merck et al. JOURNAL OF IMMUNOLOGY
- Defucosylated Anti-CCR4 Monoclonal Antibody Exerts Potent ADCC against Primary ATLL Cells Mediated by Autologous Human Immune Cells in NOD/Shi-scid, IL-2R null Mice In Vivo
- (2009) A. Ito et al. JOURNAL OF IMMUNOLOGY
- Monoclonal antibodies for cancer immunotherapy
- (2009) Louis M Weiner et al. LANCET
- Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
- (2008) M. Peipp et al. BLOOD
- Effector mechanisms of therapeutic antibodies against ErbB receptors
- (2008) Matthias Peipp et al. CURRENT OPINION IN IMMUNOLOGY
- Human Neutrophil Fcγ Receptors Initiate and Play Specialized Nonredundant Roles in Antibody-Mediated Inflammatory Diseases
- (2008) Naotake Tsuboi et al. IMMUNITY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Copy number ofFCGR3B,which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake
- (2008) Lisa C. Willcocks et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells
- (2008) J. O. Richards et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started